

# WELCOMING ADDRESS:



**DENIS HORGAN**

**Executive Director, European Alliance  
for Personalised Medicine**

# A TRULY COLLABORATIVE GATHERING

## 150+ participants on-site

→ Bringing together policymakers, researchers, industry, and patient voices under one roof.


## 80+ distinguished speakers

→ Experts shaping the future of personalised medicine through plenaries, workshops, and debates.


## 450+ online participants

→ Extending the conversation beyond the conference hall, ensuring global reach and inclusivity.

**Together, this diverse community will exchange ideas, challenge assumptions, and co-create the roadmap for Europe's personalised healthcare future.**




# ONE VISION, MANY VOICES



European Alliance for  
Personalised Medicine



- Our journey to Vision Europe 2030 celebrates unity of purpose, but we must also embrace diverse needs, expectations, and perspectives.
- Personalised medicine thrives at the intersection of shared goals and individual differences.



# BREAKING BARRIERS TO ACCESS




- Access remains a key challenge.
- Too often, those most in need cannot fully participate due to barriers in infrastructure, healthcare access, or social determinants.
- In Vision Europe 2030, our task is to ensure inclusion and equal opportunity for all patients.



# INVESTING TODAY FOR TOMORROW'S HEALTH



- Initial investments in research and innovation may seem costly.
- But personalised medicine pays for itself by driving better outcomes, efficiency, and long-term sustainability.



European Alliance for  
Personalised Medicine



# EVIDENCE FIRST, FLEXIBILITY ALWAYS



European Alliance for  
Personalised Medicine

- We must remain evidence-based, not guided by superstition or outdated models.
- At the same time, healthcare systems must stay flexible—to adapt to disruptive technologies and evolving patient needs.




# BEYOND ONE-SIZE-FITS-ALL




European Alliance for  
Personalised Medicine


- Personalised medicine is not one-size-fits-all.
- It is not about “take one of mine”, but about tailoring treatments to each patient’s biology, environment, and values.



# DATA: THE LIFELOOD OF PERSONALISED MEDICINE



- Big data, small data, each patient's data matters.
- Unlocking the potential of both population-level insights and individual contributions is essential for next-gen treatments.



# AGENDA: DAY 1 – SEPTEMBER 2ND, 2025



Time	Session Title	Moderator / Chair
09.15 – 10.30	Tech for Equity: Catalyzing Innovation in High-Income Cancer Systems	Jose M. Martin-Moreno, University of Valencia & Spanish Economy and Health Foundation
10.30 – 11.30	Democratizing Trials – Blueprint for Inclusive Innovation	Antoni Moliner Montseratt, ALAN – Maladies Rares Luxembourg
12.00 – 13.00	Precision Oncology 2.0 – From RCT-Centered Models to Innovation-Ready Systems	Jose M. Martin-Moreno, University of Valencia & Spanish Economy and Health Foundation
14.00 – 15.00	Public–Private Power Plays – Building Sustainable Partnerships	Josep Figueras, European Observatory on Health Systems and Policies
15.30 – 16.30	Spotlight 1: Bridging the Innovation Gap – Precision Cardiology	Donna Fitzsimons, Queen's University Belfast, former ESC Board Member
16.30 – 17.30	Spotlight 2: Bridging the Innovation Gap – Precision Neurology	Frédéric Destrebecq, European Brain Council
18.45 – 22.00	Cocktail Reception & Working Dinner – Keep the Person in Personalised HealthCare (By Invitation Only)	Josep Figueras, European Observatory on Health Systems and Policies

# AGENDA: DAY 2 – SEPTEMBER 3RD, 2025



Time	Session Title	Moderator / Chair
09.00 – 10.00	Innovation Without Access Is Failure – Delivering Genomic Equity	Jose M. Martin-Moreno, University of Valencia & Spanish Economy and Health Foundation
10.00 – 11.00	Data That Delivers – Building a Smarter, Sustainable Healthcare Data System	Antoni Moliner Montseratt, ALAN – Maladies Rares Luxembourg
11.30 – 12.30	Choose Europe, Back Health – Translating the Draghi Vision	Phil Hogan, Former EU Commissioner for Trade
14.00 – 15.00	Spotlight 3: Precision Frontiers in Chronic Disease – Global Strategy	Ruggero De Maria, Italian Alliance Against Cancer & Università Cattolica del Sacro Cuore, Rome
15.00 – 15.45	Screening Reimagined for a Digital, AI-Enabled Future	Elil Renganathan, Monash University Malaysia
15.45 – 16.30	Concluding Session – Toward a Technology-Driven Cancer Control Framework	Josep Figueras, European Observatory on Health Systems and Policies



# OUR MODERATORS/CHAIR:



**JOSE M. MARTIN-MORENO**

Professor of Medicine and Public Health, University of Valencia & Chair of Innovative Health Management, Spanish Economy and Health Foundation



**ANTONI MOLINER MONSERATT**

Vice président - ALAN Vice President of the National Committee of the Rare Diseases Plan of Luxembourg



**JOSEP FIGUERAS**

Director Emeritus, European Observatory on Health Systems and Policies



**FRÉDÉRIC DESTREBECQ**

Executive Director, European Brain Council



**DONNA FITZSIMONS**

Head of Nursing & Midwifery, Queen's University Belfast & former ESC Board Member



# OUR MODERATORS/CHAIR:



**PHIL HOGAN**

Former EU Commissioner for Trade



**RUGGERO DE MARIA**

President, Italian Alliance Against  
Cancer (Alleanza Contro il  
Cancro), Professor of Pathology,  
Università Cattolica del Sacro  
Cuore, Rome



**ELIL RENGANATHAN**

Professor, Public Health and Policy,  
Jeffrey Cheah School of  
Medicine and Health Sciences,  
Monash University Malaysia



# OUR RAPPORTEURS:



**DENIS HORGAN**

Executive Director, European Alliance  
for Personalised Medicine



**ELIL RENGANATHAN**

Professor, Public Health and  
Policy, Jeffrey Cheah School  
of Medicine and  
Health Sciences, Monash  
University Malaysia



**MUIRIS O'CONNOR**

Assistant Secretary, Department of  
Health, Ireland



**TILMAN KRUEGER**

MSD, Director  
Oncology Policy EU &  
Pipeline



**MARILYS CORBEX**

Senior Technical Officer, WHO Europe

# **TOGETHER, OVER THESE TWO DAYS, WE WILL:**

- Explore disruptive technologies**
- Democratize clinical trials**
- Shape next-generation treatment paradigms**
- Let us move from vision to reality, for patients, for science, for Europe.**

